Regulus Therapeutics Inc. (Nasdaq: RGLS), a pioneering biopharmaceutical company renowned for its leadership in microRNA research, is excited to announce a significant funding milestone of $100 million. Based in San Diego, California, Regulus is at the forefront of discovering and developing innovative medicines that target microRNAs, a class of molecules known to play critical roles in regulating gene expression. This substantial investment is poised to accelerate the company’s well-balanced microRNA therapeutics pipeline, further bolstering its expertise in oligonucleotide drug discovery and development. In addition to enhancing its development pipeline, the funding will drive the advancement of the microMarkersSM biomarkers platform, a sophisticated tool designed to facilitate more precise patient diagnosis and treatment monitoring.
Led by a seasoned executive team with extensive experience in corporate management, business growth, science, and drug development, Regulus is firmly committed to transforming innovative research into tangible therapeutics. The support from this funding round not only reinforces Regulus’ position as a market leader in the realm of microRNA therapeutics but also provides the financial resources necessary for the company to expand its robust intellectual property estate. Furthermore, collaboration with a world-class scientific advisory board—composed of some of the foremost authorities in microRNA research—will empower Regulus to refine its strategies and enhance its scientific endeavors. Ultimately, this new infusion of capital will enable Regulus Therapeutics to continue pushing the boundaries of what is possible in the treatment of various diseases, accelerating clinical development and promising a brighter future for patients worldwide.
